JP2002534687A - 過分極を使用したｎｍｒ分光学アッセイ - Google Patents
過分極を使用したｎｍｒ分光学アッセイInfo
- Publication number
- JP2002534687A JP2002534687A JP2000592655A JP2000592655A JP2002534687A JP 2002534687 A JP2002534687 A JP 2002534687A JP 2000592655 A JP2000592655 A JP 2000592655A JP 2000592655 A JP2000592655 A JP 2000592655A JP 2002534687 A JP2002534687 A JP 2002534687A
- Authority
- JP
- Japan
- Prior art keywords
- assay
- nmr
- hyperpolarization
- assay reagent
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000003556 assay Methods 0.000 title claims abstract description 166
- 238000005481 NMR spectroscopy Methods 0.000 title claims abstract description 81
- 230000002102 hyperpolarization Effects 0.000 title claims abstract description 39
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 91
- 238000003384 imaging method Methods 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 76
- 230000010287 polarization Effects 0.000 claims description 37
- 239000000126 substance Substances 0.000 claims description 30
- 230000005291 magnetic effect Effects 0.000 claims description 27
- 239000007789 gas Substances 0.000 claims description 21
- 229910052756 noble gas Inorganic materials 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 238000012360 testing method Methods 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 125000003729 nucleotide group Chemical class 0.000 claims description 12
- 238000001228 spectrum Methods 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 11
- 230000005540 biological transmission Effects 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims description 10
- 108091033319 polynucleotide Chemical class 0.000 claims description 10
- 239000002157 polynucleotide Chemical class 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 9
- 238000012546 transfer Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 150000002894 organic compounds Chemical group 0.000 claims description 6
- 230000003595 spectral effect Effects 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 238000004904 shortening Methods 0.000 claims description 5
- 210000004748 cultured cell Anatomy 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 239000002207 metabolite Substances 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000002474 experimental method Methods 0.000 claims description 3
- 238000000099 in vitro assay Methods 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 238000004611 spectroscopical analysis Methods 0.000 claims description 3
- 238000000159 protein binding assay Methods 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 230000036962 time dependent Effects 0.000 claims description 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 claims 1
- 238000007899 nucleic acid hybridization Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000004458 analytical method Methods 0.000 abstract description 4
- 210000004940 nucleus Anatomy 0.000 description 60
- 239000000523 sample Substances 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 230000005298 paramagnetic effect Effects 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- -1 amino acids amino acids Chemical class 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 229910052724 xenon Inorganic materials 0.000 description 4
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005388 cross polarization Methods 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000005004 MAS NMR spectroscopy Methods 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 101000860173 Myxococcus xanthus C-factor Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 238000004333 Waugh-Huber-Haeberlen sequence Methods 0.000 description 1
- 229910052768 actinide Inorganic materials 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910001430 chromium ion Inorganic materials 0.000 description 1
- RKCWRYBOSIJRNH-UHFFFAOYSA-N chromium(5+) Chemical compound [Cr+5] RKCWRYBOSIJRNH-UHFFFAOYSA-N 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- UCNNJGDEJXIUCC-UHFFFAOYSA-L hydroxy(oxo)iron;iron Chemical compound [Fe].O[Fe]=O.O[Fe]=O UCNNJGDEJXIUCC-UHFFFAOYSA-L 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 238000004958 nuclear spectroscopy Methods 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002907 paramagnetic material Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 238000010996 solid-state NMR spectroscopy Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/28—Details of apparatus provided for in groups G01R33/44 - G01R33/64
- G01R33/281—Means for the use of in vitro contrast agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Optics & Photonics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9828852.5A GB9828852D0 (en) | 1998-12-30 | 1998-12-30 | Nmr spectroscopy method |
| GBGB9918096.0A GB9918096D0 (en) | 1999-08-02 | 1999-08-02 | NMR Spectroscopy method |
| GB9828852.5 | 1999-08-02 | ||
| GB9918096.0 | 1999-08-02 | ||
| PCT/GB1999/004410 WO2000040988A1 (en) | 1998-12-30 | 1999-12-23 | Nmr spectroscopic in vitro assay using hyperpolarization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002534687A true JP2002534687A (ja) | 2002-10-15 |
| JP2002534687A5 JP2002534687A5 (enExample) | 2007-02-15 |
Family
ID=26314943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000592655A Pending JP2002534687A (ja) | 1998-12-30 | 1999-12-23 | 過分極を使用したｎｍｒ分光学アッセイ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7501236B1 (enExample) |
| EP (1) | EP1141738A1 (enExample) |
| JP (1) | JP2002534687A (enExample) |
| AU (1) | AU766923B2 (enExample) |
| CA (1) | CA2356442C (enExample) |
| IL (2) | IL143927A0 (enExample) |
| WO (1) | WO2000040988A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006508359A (ja) * | 2002-11-29 | 2006-03-09 | アメルシャム ヘルス アクスイェ セルスカプ | リガンド又は標的を過分極させて核磁気共鳴スペクトルをリガンド又は標的の参照スペクトルと比較するリガンドの核磁気共鳴検出法 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9911681D0 (en) | 1999-05-19 | 1999-07-21 | Nycomed Imaging As | Process |
| GB0014463D0 (en) * | 2000-06-14 | 2000-08-09 | Nycomed Amersham Plc | NMR Method |
| GB0022341D0 (en) * | 2000-09-12 | 2000-10-25 | Nycomed Imaging As | Method |
| NO20023358D0 (no) * | 2002-04-19 | 2002-07-11 | Amersham Health As | Metode |
| NO20023357D0 (no) * | 2002-04-19 | 2002-07-11 | Amersham Health As | Blanding |
| GB0219953D0 (en) * | 2002-08-29 | 2002-10-02 | Amersham Health R & D Ab | An arrangement and a method for providing contrast agents |
| GB0308586D0 (en) | 2003-04-14 | 2003-05-21 | Amersham Health R & D Ab | Method and arrangements in NMR spectroscopy |
| NO20035626D0 (no) * | 2003-12-17 | 2003-12-17 | Amersham Health As | Metode |
| EP1555538A1 (en) * | 2004-01-15 | 2005-07-20 | Bruker BioSpin MRI GmbH | Method of fast multidimensional NMR spectroscopy |
| EP1998813A2 (en) * | 2006-03-29 | 2008-12-10 | GE Healthcare AS | Method to produce hyperpolarised carboxylates and sulphonates in the presence of inorganic cations |
| EP2117607A4 (en) * | 2007-01-11 | 2012-08-08 | Huntington Medical Res Inst | PICTURES AND METHOD FOR THEIR USE |
| US20100233089A1 (en) * | 2007-10-05 | 2010-09-16 | Huntington Medical Research Institutes | Imaging of genetic material with magnetic resonance |
| EP2902041A1 (en) * | 2007-12-19 | 2015-08-05 | GE Healthcare Limited | Composition and method for generating a metabolic profile using 13C-MR detection |
| WO2009129265A1 (en) * | 2008-04-14 | 2009-10-22 | Huntington Medical Research Institutes | Methods and apparatus for pasadena hyperpolarization |
| US9678185B2 (en) | 2013-03-15 | 2017-06-13 | Pepsico, Inc. | Method and apparatus for measuring physico-chemical properties using a nuclear magnetic resonance spectrometer |
| US10338052B2 (en) | 2015-11-30 | 2019-07-02 | Vanderbilt University | Methods of detecting sulfur-containing compounds |
| US20180230182A1 (en) * | 2017-02-15 | 2018-08-16 | Cedars-Sinai Medical Center | Hyperpolarization of amino acid residues for producing hyperpolarized peptides |
| DE102018203434B4 (de) * | 2018-03-07 | 2019-12-05 | Bernd Willi Karl-Heinz Diehl | Verfahren zur heteronuklearen quantitativen Bestimmung mittels NMR-Spektroskopie, Referenzsubstanzen hierfür und Verfahren zur Bestimmung des Deuterierungsgrades einer deuterierten Verbindung |
| WO2022238350A1 (en) | 2021-05-11 | 2022-11-17 | Ecole Polytechnique Federale De Lausanne (Epfl) | Dnp biosensor |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07506192A (ja) * | 1993-02-05 | 1995-07-06 | マーテック・バイオサイエンシス・コーポレイション | タンパク質構造決定のための組成物類および方法類 |
| WO1997018471A1 (en) * | 1995-11-14 | 1997-05-22 | Abbott Laboratories | Use of nuclear magnetic resonance to identify ligands to target biomolecules |
| WO1997037239A1 (en) * | 1996-03-29 | 1997-10-09 | Lawrence Berkeley National Laboratory | Enhancement of nmr and mri in the presence of hyperpolarized noble gases |
| JPH10501708A (ja) * | 1994-04-08 | 1998-02-17 | ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク | 過分極した貴ガスを利用した磁気共鳴映像化 |
| WO1998048264A1 (en) * | 1997-04-18 | 1998-10-29 | Abbott Laboratories | Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834226A (en) * | 1991-01-31 | 1998-11-10 | Xytronyx, Inc. | One-step test for aspartate aminotransferase |
| US6103492A (en) * | 1993-03-08 | 2000-08-15 | Indiana University | Polynucleotide encoding mu opioid receptor |
| US5475304A (en) | 1993-10-01 | 1995-12-12 | The United States Of America As Represented By The Secretary Of The Navy | Magnetoresistive linear displacement sensor, angular displacement sensor, and variable resistor using a moving domain wall |
| US5479925A (en) | 1994-06-23 | 1996-01-02 | General Electric Company | Magnetic resonance (MR) angiography in a low-field imaging magnet |
| EP0904542B1 (en) * | 1996-03-01 | 2005-06-29 | Beckman Coulter, Inc. | System for simultaneously conducting multiple ligand binding assays |
| US6278893B1 (en) * | 1998-01-05 | 2001-08-21 | Nycomed Imaging As | Method of magnetic resonance imaging of a sample with ex vivo polarization of an MR imaging agent |
| US6574496B1 (en) * | 1999-05-19 | 2003-06-03 | Amersham Health As | Magnetic resonance imaging |
-
1999
- 1999-12-23 EP EP99962446A patent/EP1141738A1/en not_active Ceased
- 1999-12-23 US US09/869,629 patent/US7501236B1/en not_active Expired - Fee Related
- 1999-12-23 IL IL14392799A patent/IL143927A0/xx active IP Right Grant
- 1999-12-23 JP JP2000592655A patent/JP2002534687A/ja active Pending
- 1999-12-23 CA CA002356442A patent/CA2356442C/en not_active Expired - Fee Related
- 1999-12-23 WO PCT/GB1999/004410 patent/WO2000040988A1/en not_active Ceased
- 1999-12-23 AU AU18803/00A patent/AU766923B2/en not_active Ceased
-
2001
- 2001-06-21 IL IL143927A patent/IL143927A/en not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07506192A (ja) * | 1993-02-05 | 1995-07-06 | マーテック・バイオサイエンシス・コーポレイション | タンパク質構造決定のための組成物類および方法類 |
| JPH10501708A (ja) * | 1994-04-08 | 1998-02-17 | ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク | 過分極した貴ガスを利用した磁気共鳴映像化 |
| WO1997018471A1 (en) * | 1995-11-14 | 1997-05-22 | Abbott Laboratories | Use of nuclear magnetic resonance to identify ligands to target biomolecules |
| WO1997037239A1 (en) * | 1996-03-29 | 1997-10-09 | Lawrence Berkeley National Laboratory | Enhancement of nmr and mri in the presence of hyperpolarized noble gases |
| WO1998048264A1 (en) * | 1997-04-18 | 1998-10-29 | Abbott Laboratories | Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules |
Non-Patent Citations (4)
| Title |
|---|
| JPN5002002876, Ｐａｕｌ Ｊ．Ｒ．Ｓｐｏｏｎｅｒ ｅｔ ａｌ．, ＢＩＯＰＨＹＳＩＣＡＬ ＪＯＵＲＮＡＬ, 19981201, Ｖｏｌ．７５ Ｎｏ．６, ｐｐ．２７９４−２８００, US * |
| JPN5002002877, Ｊｏｈａｎｎｅｓ Ｎａｔｔｅｒｅｒ ｅｔ ａｌ．, ＰＲＯＧＲＥＳＳ ＩＮ ＮＵＣＬＥＡＲ ＭＡＧＮＥＴＩＳＣ ＲＥＳＯＮＡＮＣＥ ＳＰＣＴＲＯＳＣＯＰＹ, 19971101, Ｖｏｌ．３１ Ｎｏ．４, ｐｐ．２９３−３１５ * |
| JPN5002002878, Ｊ．Ｈ．Ａｒｄｅｎｋｊａｅｒ−Ｌａｒｓｅｎ ｅｔ ａｌ．, ＪＯＵＲＮＡＬ ＯＦ ＭＡＧＮＥＴＩＣ ＲＥＳＯＮＡＮＣＥ, 19980701, Ｖｏｌ．１３３ Ｎｏ．１, ｐｐ．１−１２, US * |
| JPN5002002879, Ｄｅｎｎｉｅｓ Ａ．Ｈａｌｌ, ＳＣＩＥＮＣＥ, 19970509, Ｖｏｌ．２７６ Ｎｏ．５３１４, ｐｐ．９３０−９３２, US * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006508359A (ja) * | 2002-11-29 | 2006-03-09 | アメルシャム ヘルス アクスイェ セルスカプ | リガンド又は標的を過分極させて核磁気共鳴スペクトルをリガンド又は標的の参照スペクトルと比較するリガンドの核磁気共鳴検出法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US7501236B1 (en) | 2009-03-10 |
| CA2356442C (en) | 2009-03-24 |
| AU1880300A (en) | 2000-07-24 |
| EP1141738A1 (en) | 2001-10-10 |
| CA2356442A1 (en) | 2000-07-13 |
| WO2000040988A1 (en) | 2000-07-13 |
| IL143927A (en) | 2007-05-15 |
| IL143927A0 (en) | 2002-04-21 |
| AU766923B2 (en) | 2003-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002534687A (ja) | 過分極を使用したｎｍｒ分光学アッセイ | |
| Zhou et al. | The relayed nuclear Overhauser effect in magnetization transfer and chemical exchange saturation transfer MRI | |
| Spence et al. | Development of a functionalized xenon biosensor | |
| US8372654B2 (en) | Method for investigating the fate of a test compound or the stateof a biological system by means of NMR of hyperpolarised NMR active nuclei | |
| Haun et al. | Magnetic nanoparticle biosensors | |
| Chen et al. | 19F NMR: a valuable tool for studying biological events | |
| van Dongen et al. | Structure-based screening and design in drug discovery | |
| EP2069769B1 (en) | Method of detecting interactions on a microarray using nuclear magnetic resonance | |
| Bernadó et al. | Macromolecular crowding in biological systems: hydrodynamics and NMR methods | |
| Tiburu et al. | Development of magnetically aligned phospholipid bilayers in mixtures of palmitoylstearoylphosphatidylcholine and dihexanoylphosphatidylcholine by solid-state NMR spectroscopy | |
| Luo et al. | New frontiers in in vitro medical diagnostics by low field T2 magnetic resonance relaxometry | |
| Ravera et al. | NMR spectroscopy and metal ions in life sciences | |
| Pouliquen et al. | Physicochemical properties of structured water in human albumin and gammaglobulin solutions | |
| US7557573B2 (en) | NMR-based methods for detecting ligands, where the ligand or target are hyperpolarized and the NMR-spectrum is compared with a reference spectrum of the ligand or target | |
| Siegal et al. | Biomolecular NMR: recent advances in liquids, solids and screening | |
| LeBlanc et al. | A drug discovery toolbox for Nuclear Magnetic Resonance (NMR) characterization of ligands and their targets | |
| Alsina-Bolívar et al. | J-coupling NMR spectroscopy with nitrogen vacancy centers at high fields | |
| Salvi | Applications of Hyperpolarisation and NMR Long-Lived States in Drug Screening | |
| Levy et al. | Recent developments in nuclear magnetic resonance spectroscopy | |
| JP2002534683A (ja) | Ｎｍｒ分光法 | |
| Wang et al. | Proton on-resonance rotating frame spin lattice relaxation measurements of B and Z double-helical oligodeoxyribonucleotides in solution | |
| Qi | Characterization of Ligand Binding Using Dissolution DNP Assisted NMR Spectroscopy | |
| Overman | Magnetic Resonance Makes the Invisible Visible | |
| Xu | The Development and Applications of Nuclear Magnetic Resonance Spectroscopy in Surface Interaction of Nanoparticles | |
| EP1514108A2 (en) | Methods for identifying ligands using waterlogsy nmr |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20041124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20041217 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20041217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061221 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061221 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091208 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100305 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100305 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100305 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100312 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100408 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100415 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100507 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100514 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100608 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100623 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100720 |